The OJC Episode 27: I’m Sorry Miss Eva

Pinterest LinkedIn Tumblr +

Anna Nowak on CheckMate 743 and DREAM3R, Fractals, Elfstedentocht, DPD genotyping, Antibody–drug Conjugates, Coronary Artery Disease, Dr Glaucomflecken and much more…

The Oncology Podcast, brought to you by Oncology News Australia, is proud to present Episode 27 in our series The Oncology Journal Club.

This week’s episode is in our usual format featuring some amazing papers and of course, it wouldn’t be the OJC without a few weird and wonderful updates as well, including Twitter account of the week, the amazing paper of the week, some homework on fractals and much more.

Craig gets us started with a paper on Durvalumab and has a fascinating interview with Professor Anna Nowak. Eva our Twitter Poll Queen gives us insight into DPD genotyping, with a consensus statement by the German Society for Hematology and Medical Oncology on testing.

Hans has some fascinating updates for us too, talking us through a paper titled ‘Meta-analysis of tumor- and T cell-intrinsic mechanisms of sensitization to checkpoint inhibition’ and he also explains the famous Elfstedentocht or the ‘Eleven Cities Tour’…

Elfstedentocht, 26 February 1986. Evert van Benthem in Bartlehiem. Source:

About The Oncology Journal Club:

We have taken an old concept and updated it with a new format. In each episode a team of expert contributors will review topical journal papers and interview special guests who are leaders in their fields to help keep you informed of the latest developments on the go.

With The Oncology Podcast – and The Oncology Journal Club in particular – we are aiming to deliver oncology news differently,” Rachael Babin, Editor-in-Chief, Oncology News.

The Oncology Journal Club is hosted by Professor Eva Segelov, from Monash University. Eva is joined by Dr Craig Underhill from Albury-Wodonga and Professor Hans Prenen from Antwerp, Belgium. We hope you enjoy listening and find this a valuable and entertaining resource.

This Week’s Papers:

  1. Wikipedia entry for Elfstedentocht – the Eleven cities tour
  2. Sheth S, et al. Durvalumab activity in previously treated patients who stopped durvalumab without disease progression. Journal for ImmunoTherapy of Cancer 2020;8:e000650. doi: 10.1136/jitc-2020-000650. Access online here. 
  3. Wörmann B, et al. Dihydropyrimidine Dehydrogenase Testing prior to Treatment with 5-Fluorouracil, Capecitabine, and Tegafur: A Consensus Paper. Oncol Res Treat. 2020;43(11):628-636. doi: 10.1159/000510258. Epub 2020 Oct 23. PMID: 33099551. Access online here.
  4. Litchfield K, et al. Meta-analysis of tumor- and T cell-intrinsic mechanisms of sensitization to checkpoint inhibition. Cell. 2021 Feb 4;184(3):596-614.e14.

This Week’s Interview:

  1. Baas, P,. et al. First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial. The Lancet. Volume 397, Issue 10272, 375 – 386. Published: January 21, 2021. DOI:
  2. Information on DREAM3R Trial:

This Week’s Quick Bites:

  1. Drago, J.Z., Modi, S. & Chandarlapaty, S. Unlocking the potential of antibody–drug conjugates for cancer therapy. Nat Rev Clin Oncol (2021). Access online here.
  2. van Roessel, S,. et al. Axial slicing versus bivalving in the pathological examination of pancreatoduodenectomy specimens (APOLLO): a multicentre randomized controlled trial. HPBAccess online here.
  3. Holm Milo, ML, et al. Risk of coronary artery disease after adjuvant radiotherapy in 29,662 early breast cancer patients: A population-based Danish Breast Cancer Group study. Radiotherapy and Oncology. Published: January 27, 2021 DOI: Access online here.
  4. The Oncology Journal Club Episode 17: Cardio Oncology Special
  5. Cousin S, et al. Regorafenib-Avelumab combination in patients with microsatellite stable colorectal cancer (REGOMUNE) : a single arm, open-label, phase II trial. Clin Cancer Res. 2021 Jan 25:clincanres.3416.2020. Access online here.
  6. Jin S, et al. Efficient detection and post-surgical monitoring of colon cancer with a multi-marker DNA methylation liquid biopsy. Proc Natl Acad Sci USA. 2021 Feb 2;118(5):e2017421118. doi: 10.1073/pnas.2017421118. Access online here.
  7. Kawazoe A, et al. Safety and activity of trifluridine/tipiracil and ramucirumab in previously treated advanced gastric cancer: an open-label, single-arm, phase 2 trial. Lancet Gastroenterol Hepatol. 2021 Jan 25:S2468-1253(20)30396-4. doi: 10.1016/S2468-1253(20)30396-4. Epub ahead of print.  Access online here.
  8. Mooi J, et al. Dual anti-angiogenesis agents bevacizumab plus trebananib, without chemotherapy, in first-line treatment of metastatic colorectal cancer: results of a phase II study. Clin Cancer Res. 2021 Jan 29:clincanres.2714.2020. doi: 10.1158/1078-0432.CCR-20-2714. Access online here.
  9. Rugo HS, Im S, Cardoso F, et al. Efficacy of Margetuximab vs Trastuzumab in Patients With Pretreated ERBB2-Positive Advanced Breast Cancer: A Phase 3 Randomized Clinical Trial. JAMA Oncol. Published online January 22, 2021. doi:10.1001/jamaoncol.2020.7932. Access online here.
  10. Valuing all lives equally: cancer surgery, COVID-19, and the NHS in crisis. Access online here.
  11. Paz-Ares L,. et al. First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial. Lancet Oncol. 2021 Feb;22(2):198-211. doi: 10.1016/S1470-2045(20)30641-0. Epub 2021 Jan 18. Erratum in: Lancet Oncol. 2021 Mar;22(3):e92. PMID: 33476593. Access online here.

Amazing Article of the Week:

Tabner A, et al. Paediatricians: Are they just little adults? 
Twitter Account of the Week:
Dr Glaucomflecken @DGlaucomflecken 
This Week’s Homework:
Wikipedia entry for Fractals

This Week’s Team:

Professor Eva Segelov

Eva Segelov

Professor Eva Segelov is a Medical Oncologist and is Director of Oncology at Monash University and Monash Health, Melbourne, Victoria, previously Senior Medical Oncologist at St Vincent’s Hospital, St Vincent’s Private Hospital and St Vincent’s Clinic and Associate Professor of Medicine, University of New South Wales.

Eva has an interest in academic clinical trials in GI and breast cancer and has been a member of the AGITG since 2003. She has clinical trials expertise, links with national and international trials groups, and extensive experience with adult medical education.

You can find Eva on Twitter here: @profevasegelov

Dr Craig Underhill

Craig Underhill

Dr Craig Underhill completed his Bachelor of Medicine and Surgery in 1987 at Melbourne University. He completed medical oncology training in Melbourne and worked as the Senior Clinical Research Registrar at Guy’s Hospital, London.

In 1998 arrived in Albury-Wodonga and established a medical oncology practice and clinical trials unit which has developed expertise and infrastructure to ensure the initiation of high quality trials. The research Unit lead by Dr Underhill has twice been awarded NSW Premier’s Award for Innovation in Cancer Clinical Trials, the inaugural award in 2009 and then again in 2012.

Dr Underhill chaired a working party that was instrumental in securing $65 million in federal funding for The Albury Wodonga Regional Cancer Centre which opened in September 2016.

Dr Underhill is the VCCC Regional Oncology Lead and advocates for the increased access to clinical trials for regional Victorians and leads the VCCC teletrials program.

You can find Craig on Twitter here: @CraigUnderhill

Professor Hans Prenen

Hans Prenen

Professor Hans Prenen is a medical oncologist and head of the phase 1 – early clinical trials unit at the Antwerp University Hospital in Belgium. He is a member of several scientific organisations, published many scientific oncology papers in prestigious journals and is regularly invited for lectures at national and international meetings.  His interests are clinical trials and translational research with a focus on digestive oncology.

You can find Hans on Twitter here: @HPrenen


Professor Anna Nowak

Professor Anna Nowak is the current Director of the National Centre for Asbestos Related Diseases (NCARD). She is a Medical Oncologist at Sir Charles Gairdner Hospital (SCGH) and Professor of Medicine at the University of Western Australia (UWA), with research and clinical interests in thoracic cancers and malignant mesothelioma, and neuro-oncology. Her research training includes a laboratory-based PhD thesis in tumour immunology followed by a postdoctoral fellowship in clinical trials and quality of life research, giving her a unique translational perspective with expertise in laboratory science, clinical trials, patient-rated outcomes and quality of life. She was amongst the earliest researchers demonstrating that chemotherapy and immunotherapy could be synergistic treatment modalities in cancer treatment, rather than antagonistic. This belief is now widely held and has directly led to the development of two early phase clinical trials at SCGH, run over the last 5 years, in addition to the national DREAM trial and International DREAM3R trial.

You can find Anna on Twitter: @perth_meso_dr

Rachael Babin

Rachael Babin

Rachael Babin is Editor-in-Chief of The Oncology Newsletter and Publisher of For regular oncology updates for healthcare professionals, please subscribe to The Oncology Newsletter.

With thanks to Eva Segelov, Craig Underhill, Hans Prenen, Anna Nowak and Graham Knowles.


About Author

The ONA Editor curates oncology news, views and reviews from Australia and around the world for our readers. In aggregated content, original sources will be acknowledged in the article footer.

Leave A Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.